As of 2019, there were about 2,010 biotech venture
companies active in Japan. Of these,
only a few companies have succeeded in launching
new drugs to the Japanese market.
*Source: Japan Bioindustry Association, Survey and analysis of the current situation of domestic bio-related ventures
So, why has DWTI been able to successfully launch a drug?
- We were fortunate in the disease type we chose for drug development. (Few companies in Japan were working on ophthalmic drugs, and hence we had few rivals.)
- We had an excellent compound. (We benefited from the high quality of our compound library.*)
*Drug discovery research seeks to discover new drug candidate compounds drawing from a compound library, a collection of promising new drug seeds, including drugs that have already been launched.
GLANATEC® ophthalmic solution 0.4% “successfully launched”
- Sales started in December 2014
- A treatment for glaucoma and high intraocular pressure
- Glaucoma affects 1 in 20 people over the age of 40 in Japan
- The licensee for GLANATEC® is Kowa Co., Ltd.
- The drug uses a world-first novel mechanism not found in any other eye drop